Lumos Diagnostics Holdings Ltd
ASX:LDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.8), the stock would be worth AU$-0.06 (135% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -39.9 | AU$0.17 |
0%
|
| Industry Average | 13.8 | AU$-0.06 |
-135%
|
| Country Average | 13.2 | AU$-0.05 |
-133%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
129.9m AUD | -39.9 | -9.7 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 38.4 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 16.1 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 13.7 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 22.8 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 12.2 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 19.7 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 22 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.3B CNY | 25.5 | 22.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -86.1 | -36.2 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
